Atossa director granted 10,000 RSUs

Finn Jonathan reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Finn Jonathan reported acquisition or exercise transactions in this Form 4 filing.

Atossa Therapeutics director Jonathan Finn received an equity grant of 10,000 shares of Common Stock in the form of restricted stock units. The award was granted at no cash cost per share and is compensation-related, not an open-market purchase. After the grant, Finn directly holds 11,666 shares. According to the footnote, each RSU represents a contingent right to receive one share of Common Stock, and the RSUs shall vest on the first anniversary of May 12, 2026.

Insider Trade Summary

Grant/Award: 10,000 shares

Grant/Award 1 txn

Insider Finn Jonathan

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	10,000	$0.00	$0.00

Holdings After Transaction: Common Stock — 11,666 shares (Direct)

Footnotes (1)

1. F1. Represents a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest on the first anniversary of May 12, 2026.

Key Figures

RSU grant size: 10,000 shares Grant price: $0.0000 per share Post-grant holdings: 11,666 shares +1 more

4 metrics

RSU grant size 10,000 shares Restricted stock unit award to director Jonathan Finn

Grant price $0.0000 per share Reported transaction price for RSU grant

Post-grant holdings 11,666 shares Total Common Stock held directly after transaction

Vesting schedule First anniversary of May 12, 2026 RSUs vesting term from footnote

Key Terms

restricted stock units ("RSUs"), contingent right, vest, Common Stock

4 terms

restricted stock units ("RSUs") financial

"Represents a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right..."

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

contingent right financial

"Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."

vest financial

"The RSUs shall vest on the first anniversary of May 12, 2026."

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

Common Stock financial

"Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ATOS director Jonathan Finn report?

Jonathan Finn reported an acquisition of 10,000 shares of Atossa Therapeutics Common Stock through a grant of restricted stock units. This was a compensation-related award, not an open-market purchase, and increased his direct holdings to 11,666 shares after the transaction.

Was the ATOS insider transaction a stock purchase or a grant?

The ATOS insider transaction was a grant, not a purchase. Jonathan Finn received 10,000 restricted stock units as an award, recorded with transaction code A, meaning a grant, award, or other acquisition at a stated price of $0.00 per share.

How many ATOS shares does Jonathan Finn hold after this Form 4?

After this Form 4 transaction, Jonathan Finn directly holds 11,666 shares of Atossa Therapeutics Common Stock. This total includes the 10,000-share restricted stock unit grant reported, reflecting his position immediately following the award as disclosed in the filing data.

What are the vesting terms of Jonathan Finn’s ATOS RSU grant?

The grant consists of restricted stock units that each represent a contingent right to receive one share of Common Stock. According to the footnote, these RSUs shall vest on the first anniversary of May 12, 2026, subject to the standard conditions associated with such awards.

Did ATOS director Jonathan Finn pay cash for the 10,000-share award?

No, Jonathan Finn did not pay cash for the 10,000-share award. The Form 4 shows a transaction price of $0.0000 per share, indicating this was a compensation-related restricted stock unit grant rather than an open-market stock purchase for cash consideration.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/14/2026 - 04:25 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Finn Jonathan

(Last) (First) (Middle)

C/O ATOSSA THERAPEUTICS, INC.

1448 NW MARKET STREET SUITE 500

(Street)

SEATTLE WASHINGTON 98107

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ATOSSA THERAPEUTICS, INC. [ ATOS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/12/2026		A		10,000(1)	A	$0	11,666	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest on the first anniversary of May 12, 2026.

	Jonathan Finn	05/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)